Antitumoral Action of New Sarcomycin Derivates

Oncology ◽  
1966 ◽  
Vol 20 (2) ◽  
pp. 99-112 ◽  
Author(s):  
M. Brunori ◽  
A. Floridi ◽  
A. Caputo ◽  
R. Giulano
Keyword(s):  
Antitumoral Action

Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines

2004 ◽  
Vol 14 (3) ◽  
pp. 183-188 ◽  
Author(s):  
Miguel Mu??oz ◽  
Ana P??rez ◽  
Marisa Rosso ◽  
Carmen Zamarriego ◽  
Rosario Rosso
Keyword(s):  
Receptor Antagonist ◽  
Cell Lines ◽  
Melanoma Cell ◽  
Human Melanoma ◽  
Human Melanoma Cell ◽  
Neurokinin 1 Receptor ◽  
Neurokinin 1 ◽  
Antitumoral Action ◽  
Melanoma Cell Lines

The Inhibitor of Cap-Dependent Translation 4E-BP1 as a Crossroad between Somatostatin Analogs and Everolimus: Mechanisms and Consequences on Combined Antitumoral Action of Both Drugs

2011 ◽  
pp. P3-248-P3-248
Author(s):  
Souad Najib ◽  
Laure Guitton-Sert ◽  
Cathy Marboeuf ◽  
Nathalie Saint-Laurent ◽  
Daniel Fourmy ◽  
...  
Keyword(s):  
Somatostatin Analogs ◽  
Antitumoral Action

scholarly journals Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2661
Author(s):  
Atanasio Pandiella-Alonso ◽  
Elena Díaz-Rodríguez ◽  
Eduardo Sanz
Keyword(s):  
Tumor Biology ◽  
Standard Of Care ◽  
Nutritional Supplement ◽  
Oral Solution ◽  
Preclinical Models ◽  
Good Tolerability ◽  
Double Edge ◽  
Life Improvement ◽  
Antitumoral Action

Ocoxin Oral Solution (OOS) is a nutritional supplement whose formulation includes several plant extracts and natural products with demonstrated antitumoral properties. This review summarizes the antitumoral action of the different constituents of OOS. The action of this formulation on different preclinical models as well as clinical trials is reviewed, paying special attention to the mechanism of action and quality of life improvement properties of this nutritional supplement. Molecularly, its mode of action includes a double edge role on tumor biology, that involves a slowdown in cell proliferation accompanied by cell death induction. Given the safety and good tolerability of OOS, and its potentiation of the antitumoral effect of other standard of care drugs, OOS may be used in the oncology clinic in combination with conventional therapies.

Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling

2016 ◽  
Vol 27 (10) ◽  
pp. 944-952 ◽  
Author(s):  
Jimeng Hu ◽  
Wenhui Zhu ◽  
Bingbing Wei ◽  
Hui Wen ◽  
Shanhua Mao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Antitumoral Action

scholarly journals TRB3 links ER stress to autophagy in cannabinoid antitumoral action

Autophagy ◽  
2009 ◽  
Vol 5 (7) ◽  
pp. 1048-1049 ◽  
Author(s):  
María Salazar ◽  
Arkaitz Carracedo ◽  
Íñigo J. Salanueva ◽  
Sonia Hernández-Tiedra ◽  
Ainara Egia ◽  
...  
Keyword(s):  
Er Stress ◽  
Antitumoral Action

scholarly journals Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 632
Author(s):  
Félicien Le Louedec ◽  
Fanny Leenhardt ◽  
Clémence Marin ◽  
Étienne Chatelut ◽  
Alexandre Evrard ◽  
...  
Keyword(s):  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Random Effect ◽  
Clinical Development ◽  
Dose Finding ◽  
Therapeutic Drug ◽  
Check Point ◽  
Economic Aspects ◽  
Check Point Inhibitors ◽  
Antitumoral Action

Immune check-point inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and their apparently random effect in terms of efficacy and toxicity. This marked pharmacodynamics variability in patients calls for reconsidering to what extent approved dosing used in clinical practice are optimal or whether they should require efforts for customization in outlier patients. To better understand whether or not dosing could be an actionable item in oncology, in this review, preclinical and clinical development of immune checkpoint inhibitors are described, particularly from the angle of dose finding studies. Other issues in connection with dosing issues are developed, such as the flat dosing alternative, the putative role therapeutic drug monitoring could play, the rise of combinatorial strategies, and pharmaco-economic aspects.

Antitumor activity of total extract of « Amanita phalloides » on Yoshida ascites tumor AH130

1969 ◽  
Vol 55 (4) ◽  
pp. 217-224 ◽  
Author(s):  
Luigi Villa ◽  
Angelo Agostoni
Keyword(s):  
Active Immunization ◽  
Amanita Phalloides ◽  
Inhibiting Activity ◽  
Ascites Tumor ◽  
Experimental Tumors ◽  
Experimental Conditions ◽  
Total Extract ◽  
Lytic Effect ◽  
Antitumoral Action

Total extract of « Amanita phalloides » Fr., when used in the experimental conditions described in this study, determines a constant inhibitory activity on transplants of Yoshida tumor in the rat. An early and clear lytic effect on tumor cells has also been demonstrated in vitro. The antitumoral action takes effect in the phase of implantation. It is not related to the two well known toxins, alpha-amanitine and phalloidine, which do not possess the activity when used separately. The substance, in the extract that exerts the inhibiting activity on ascites tumor of Yoshida has yet to be identified. In rats in which tumor grafts with total extract of Amanita phalloides did not result in growth a further implantation of the same tumor without extract was unsuccessful. This behaviour is possibly explained by a phenomenon of active immunization. Some particular problems arise from these results. It might be of interest to extend the research to other experimental tumors.

In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma

2012 ◽  
Vol 42 (9) ◽  
pp. 922-933 ◽  
Author(s):  
Zhan Qu ◽  
Yangde Zhang ◽  
Mingmei Liao ◽  
Yuxiang Chen ◽  
Jinfeng Zhao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antitumoral Action

scholarly journals Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma

2013 ◽  
Vol 4 (5) ◽  
pp. e618-e618 ◽  
Author(s):  
D Vara ◽  
C Morell ◽  
N Rodríguez-Henche ◽  
I Diaz-Laviada
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antitumoral Action
Sign in / Sign up

Export Citation Format

Share Document